# A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer

Source: https://onco.cc/trials/nct05566041/  
OnCo record `nct05566041` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Etoposide, Carboplatin and Cisplatin in small-cell lung cancer, run by EpicentRx, Inc., active and no longer recruiting.

## Summary

A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05566041 by EpicentRx, Inc., with 292 participants enrolled, started 2022-08-01 and due to reach its primary completion in 2025-12-31. Interventions recorded: RRx-001 + eLOOP Device and Cisplatin/carboplatin plus etoposide.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05566041
- Phase: 3
- Setting: REPLATINUM: A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer
- Sponsor: EpicentRx, Inc.
- Enrolled: 292

## Sources

- ClinicalTrials.gov NCT05566041: https://clinicaltrials.gov/study/NCT05566041

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Etoposide](https://onco.cc/drugs/etoposide/)
- companies: [EpicentRx](https://onco.cc/companies/epicentrx/)

---
JSON: https://onco.cc/api/v1/entities/nct05566041.json